Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amen to that Smooth L
I agree with you SL...
If we had guidelines from the FDA that would help CBD and CVSI then i would be all in on a RS , But I truly think this company can get there with out a RS ..
RS is dead we all done voted on this it is over .
Guys just don't reply to his post ! You cant teach old dogs new tricks.
We may have a runner !
I have 15 here in Louisville Kentucky 40229 There was only 6 before.
I have 15 here in Louisville Kentucky 40229
I see .Thanks for your thoughts.
You would think with this kind of news this would run up a little ! you think?
Chill you are a bummer man ! You run a good buzz
Loading !
Loading !
We need this it is about time !!
Amen to that , SL is the best !
Free the CBD
Get it going , I am in as well !
Yes, but guidance will solve many problems in this sector.
Yes will big time ,and it cant come soon enough for me !! CVSI STRONG
But I still say CVSI has better quality ! I have tried both and CVSI worked for me a lot better !
Yes you can JUST BUY BOTH STOCKS LIKE ME !!!!!!!!
I really do not know why to save my life , CVSI AND CW stock holders have to argue and fight over what the other company has and has not got over each other , In the long run it would benefit both company's stock holders shares if both company's do good ! . I just don't get it . Cvsi long and strong LOL !
yep that's what it is . That and mona
I don't know what is going on but this is getting old !
I love it , Great find !
Amen to that Space Lady, I am doing the same here !
I will buy a TON of this if it hits 20s. I am buying now !!!
That is great news , Take care
CV Sciences, Inc. to Announce First Quarter 2019 Results on May 8, 2020
BY GlobeNewswire
— 4:05 PM ET 04/30/2020
SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. ( CVSI
Loading...
Loading...
) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the quarter ended March 31, 2020, before the stock market opens on Friday, May 8, 2020. The Company will hold a conference call with the investment community at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events and at http://public.viavid.com/index.php?id=139612. The webcast will be archived for approximately 30 days.
Investors interested in participating in the live call can also dial (855) 327-6838 from the U.S. or international callers can dial (604) 235-2082. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.
A telephone replay will be available approximately two hours after the call concludes and will be available through Friday, May 15, 2020, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 10009493.
About CV Sciences, Inc. ( CVSI
Loading...
Loading...
)
CV Sciences, Inc. ( CVSI
Loading...
Loading...
) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s flagship brand of PlusCBD™ Oil products are sold at more than 5,700 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural product retail channel, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and our hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD™ Oil’s benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. ( CVSI
Loading...
Loading...
) has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
CVSciences@icrinc.com
Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com
Image: CV_Sciences_Logo_black_tm.jpg
Source: CV Sciences, Inc. ( CVSI
Loading...
Loading...
)
MORE CVSI NEWS
CV Sciences, Inc. Announces Filing of Form S-3 Shelf Registration Statement
GlobeNewswire - 8:00 AM ET 04/22/2020
BRIEF-CV Sciences Files For Mixed Shelf Of Up To $100 Million
Reuters - 6:05 PM ET 04/21/2020
CV Sciences Inc, Inst Holders, 1Q 2020 (CVSI)
DJ Realtime News - 3:05 AM ET 04/21/2020
Yes it is ,I hope it is a good one !
I hope and voted no on the reverse split . but would this help them if they did one ? . Just throwing this out there ! What do you think ?
Did the reverse split, option PASS.
I voted No to RS !!!!
CV Sciences, Inc. Receives Notice of Patent Allowance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction
BY GlobeNewswire
— 8:45 AM ET 04/06/2020
SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. ( CVSI
Loading...
Loading...
) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that on April 3, 2020, the Company learned that it will be receiving a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for the Company’s patent application 15/426,617.
The patent covers methods of treating smokeless tobacco addiction by administering pharmaceutical formulations containing CBD and nicotine. The communications between the USPTO and the Company conclude substantive examination of the patent application, which is now expected to issue as a patent once the issue fees are paid and the USPTO concludes their administrative procedures. CV Sciences ( CVSI
Loading...
Loading...
) has also filed corresponding patent applications that will allow the Company to seek similar patent protection in other key markets throughout the world.
“We are very pleased to receive this Notice of Allowance for our proprietary technology, the first-of-its-kind treatment for smokeless tobacco addiction,” said Joseph Dowling, Chief Executive Officer, CV Sciences. “This intellectual property provides us with significant value and opportunities to commercialize a novel CBD-based pharmaceutical drug addressing a significant unmet medical need. The worldwide smokeless tobacco addiction treatment market is estimated at greater than $2 billion and provides another important long-term growth channel for our company, in addition to our consumer product segment. We look forward to taking our next steps towards commercialization of CVSI-007, including discussions with potential strategic partners.”
The Company’s initial drug candidate (CVSI-007) contains nicotine and CBD to support cessation of smokeless tobacco use and addiction. Following formal issuance of the patent, expected over the coming months, CV Sciences ( CVSI
Loading...
Loading...
) will continue development efforts as the Company seeks authorization from the U.S. Food and Drug Administration (FDA) to commercialize the world’s first and only FDA-approved treatment for smokeless tobacco addiction.
About CV Sciences, Inc. ( CVSI
Loading...
Loading...
)
CV Sciences, Inc. ( CVSI ) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ Oil products are sold at more than 5,700 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD™ Oil’s benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. ( CVSI
Loading...
Loading...
) has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties
I sold some when it was at $8 that was when it got up to $9.00 . then it got down to around $4.00 and i bought more then and sold some when it got back up to $6.50 that was the last time it got to $6.50. I have been buying more every chance I get now . and holding . I do not know if it will ever get that high again until the FDA gets there's act together and get the CBD regulated ! I do see this stock hitting 6.50 around that time so i may sell some then but not all . Now that is just me ..
And i am staying !!
I have been here for 2 1/2 or 3 years
I hope it don't , but it seems like every Friday it pulls way back . EVERY FRIDAY !!! JMO From what i have seen in the last two years ..
Charlotte's Web Reports 4Q Loss Despite Revenue Growth
BY Dow Jones & Company, Inc.
— 6:53 AM ET 03/24/2020
Charlotte's Web Holdings ( CWBHF ) swung to a fourth-quarter loss despite 6% revenue growth, the company reported Tuesday.
The Colorado company, which makes CBD hemp-extract products, reported a loss of $18.8 million, or 19 cents a share, compared with a profit of $3.2 million, or two cents a share, for the same period a year earlier.
Revenue was $22.8 million, compared with $21.5 million for the same period a year earlier. Analysts were expecting revenue of $26.8 million, according to FactSet.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
03-24-20 0653ET
Copyright (c) 2020 Dow Jones & Company, Inc.
What are they going to do reverse spit . I do not want this at all